ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Dual-Anchored Clickable Peptide via SPAAC for Gelatinase-Responsive Antibacterial and Osteogenic Functions on Titanium Implants.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibacterial orthopedic implants that simultaneously promote osteointegration remain an unmet clinical challenge. Conventional enzyme-responsive antibacterial surfaces often suffer from irreversible loss of osteogenic motifs upon activation, limiting their regenerative capacity post-infection. Herein, we report a dual-anchored peptide design engineered on titanium implants (Ti-Dual) that addresses this limitation by retaining biofunctional motifs after pathogen-triggered activation. The peptide construct integrates an antimicrobial sequence (HHC36) and a cell-adhesive RGD motif connected via a gelatinase-cleavable spacer (GPLGV). Terminal azide groups enable stable dual-point grafting through SPAAC chemistry, overcoming the low grafting efficiency associated with mixed RGD grafting systems. Under physiological conditions, the constrained conformation suppresses antibacterial activity, favoring osteogenesis. Upon infection, bacterial gelatinase cleaves the linker, activating rapid and potent antibacterial effects-eliminating 99.37% of P. aeruginosa within 10 min, and 99.73% of S. aureus and 99.99% of P. aeruginosa within 120 min-while the RGD motif remains anchored, ensuring continuous cell adhesion and tissue integration. In vivo, Ti-Dual effectively eradicated multidrug-resistant P. aeruginosa, suppressed inflammatory responses, mitigated bone resorption, and enhanced osteogenesis in a rat femoral infection model. This design resolves the critical trade-off between infection responsiveness and sustained pro-regenerative function, offering a robust and adaptive strategy for infected bone defect repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.